Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: Multicenter experiences

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 11, 2013, Pages 6287-6292

  Ustaalioglu, Bala Basak Oven ^a   Unal, Olcun Umit ^b   Turan, Nedim ^c   Bilici, Ahmet ^d   Kaya, Serap ^e   Eren, Tulay ^f   Ulas, Arife ^g   Inal, Ali ^h   Berk, Veli ⁱ   Demirci, Umut ^j   Alici, Suleyman ^k   Bal, Oznur ^f   Benekli, Mustafa ^c   Gumus, Mahmut ^l  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Eylul University   (Turkey)

^c GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^e KOCAELI UNIVERSITY   (Turkey)

^f ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g ANKARA ONCOLOGY HOSPITAL   (Turkey)

^h DICLE UNIVERSITY   (Turkey)

ⁱ ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^j ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^k MEDICAL PARK HOSPITAL   (Turkey)

^l DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

more..

Author keywords

Adjuvant chemotherapy; Lymph node negative; Non small cell lung cancer; Prognosis

Indexed keywords

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NEOPLASMS; LUNG RESECTION; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84892467425     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.11.6287     Document Type: Article

References (20)

1. Arriagada R, Dunant A, Pignon JP, et al (2010). Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 28, 35-42.
2. Bouchard N, Laberge F, Raby B, et al (2008). Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital. Can Respir J, 15, 270-4.
3. Butts CA, Ding K, Seymour L, et al (2010). Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-smallcell lung cancer: updated survival analysis of JBR-10. J Clin Oncol, 28, 29-34.
4. Carbone DP, Felip E (2011). Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer, 12, 261-71.
5. Cho S, Park TI, Lee EB, et al (2012). Poor prognostic factors in surgically resected stage I non-small cell lung cancer: histopathologic and immunohistochemical analysis. Korean J Thorac Cardiovasc Surg, 45, 101-9.
6. Custodio AB, González-Larriba JL, et al (2009). Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol, 4, 891-910.
7. Custodio AB, García Sáenz JA, et al (2008). Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. Clin Transl Oncol, 10, 560-71.
8. Edge SB, Byrd DR, Compton CC (2010). AJCC Cancer Staging Manual, Seventh Edition. New York:Springer, 1-730.
9. Ioannidis G, Georgoulias V, Souglakos J (2011). How close are we to customizing chemotherapy in early non-small cell lung cancer. Ther Adv Med Oncol, 3, 185-205.
10. Kato H, Ichinose Y, Ohta M, et al (2004). Japan lung cancer research group on postsurgical adjuvant chemotherapy. a randomized trial of adjuvant chemotherapy with uraciltegafur for adenocarcinoma of the lung. N Engl J Med, 350, 1713-21.
11. Kelsey CR, Marks LB, Hollis D, et al (2009). Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer, 115, 5218-27.
12. Pignon JP, Tribodet H, Scagliotti GV, et al (2008). LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9.
13. Sangha R, Price J, Butts CA (2010). Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist, 15, 862-72.
14. Strauss GM, Herndon JE 2nd, Maddaus MA, et al (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol, 26, 5043-51.
15. Suehisa H, Toyooka S (2009). Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama, 63, 223-30.
16. Sun Z, Aubry MC, Deschamps C, et al (2006). Histologic grade is an independent prognostic factor for survival in nonsmall cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg, 131, 1014-20.
17. Visbal AL, Leighl NB, Feld R, et al (2005). Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest, 128, 2933-43.
18. Wang WL, Shen-Tu Y, Wang ZQ (2011). Prognostic Factors for survival of stage IB upper lobe non-small cell lung cancer patients: a retrospective study in Shanghai, China. Chin J Cancer Res, 23, 265-70.
19. Winget M, Fleming J, Li X, et al (2011). Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. Lung Cancer, 72, 52-8.
20. Zhang Z, Wang A, Zhan Z, et al (2012). T1aN0M0 and T1bN0M0 non-small cell lung cancer: a retrospective study of the prognosis. Thorac Cardiovasc Surg, [Epub ahead of print].